Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

NCT ID: NCT05481463

Last Updated: 2025-05-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-30
• Study Completion Date: 2025-05-10

Brief Summary

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

Detailed Description

surufatinib:250mg,QD,Q4W TAS-102:35mg/m2,D1-5,D8-12,Q4W

Conditions

Pancreatic Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

surufatinib combined with TAS-102

Surufatinib 250mg,TAS-102 35mg/m2

Group Type: EXPERIMENTAL

Surufatinib

Intervention Type: DRUG

surufatinib,250mg, qd, po, 28 days for a cycle

TAS-102

Intervention Type: DRUG

TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle

Interventions

Surufatinib

surufatinib,250mg, qd, po, 28 days for a cycle

Intervention Type: DRUG

TAS-102

TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Informed consent has been signed

2. Histologically or cytologically confirmed unresectable, locally advanced or metastatic pancreatic cancer

3. Age ≥ 18 years, ≤75 years, male or female

4. ECOG PS：0-1, expected overall survival ≥12 months

5. Patients who have previously received at least two systemic therapies for locally advanced or metastatic pancreatic cancer; patients with BRCA1/2 germline mutations have previously received platinum-containing regimens

6. Patients must have at least one measurable liver metastases (RECIST 1.1)

7. No serious organic diseases of the heart, lungs, brain and other organs

8. Patients must have adequate organ and bone marrow function

9. Women of childbearing age must have a negative pregnancy test within the first day of the study, and contraceptive methods should be taken during the study until 6 months after the last administration

Exclusion Criteria

1. Participated in clinical trials of other anti-tumor drugs within 4 weeks before enrollment

2. Previously received VEGFR inhibitors or immune checkpoint inhibitors

3. Patients had other malignant tumors in the past 5 years, except for the cured skin basal cell carcinoma and cervical carcinoma in situ

4. Patients previously had brain metastasis or current brain metastasis

5. Received any operation (except biopsy) or invasive treatment or operation (except venous catheterization, puncture and drainage, internal/external drainage surgery for obstructive jaundice, etc.) within 4 weeks before enrollment

6. Clinically significant electrolyte abnormality

7. Patient currently has uncontrolled hypertension, defined as: systolic blood pressure > 140mmHg or diastolic blood pressure > 90mmHg

8. Proteinuria ≥ 2+ (1.0g/24hr)

9. Patients whose tumor is highly likely to invade important blood vessels and cause fatal hemorrhage during the follow-up study as judged by the investigator

10. Have evidence or history of bleeding tendency within 3 months, significant bleeding symptoms or a clear bleeding tendency within 3 months before enrollment

11. Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; NYHA classification > 2 Grade; ventricular arrhythmia requiring medical therapy; ECG showing QTc interval ≥ 480 ms

12. Active or uncontrolled serious infection (≥CTCAE grade 2 infection)

13. Unrelieved toxic reactions ≥ CTCAE grade 2 due to any previous anticancer treatment, excluding alopecia, lymphopenia and neurotoxicity of ≤ grade 2 caused by oxaliplatin

14. Pregnant or lactating women

15. Any other disease, with clinically significant metabolic abnormalities, physical examination abnormalities or laboratory abnormalities, according to the judgment of investigator that the patient is not suitable for the the study drug (such as having epileptic seizures and require treatment), or would affect the interpretation of study results, or put patients at high risk

16. Clinical confirmed human immunodeficiency virus (HIV) infection, history of clinically significant liver disease, including viral hepatitis (hepatitis B / C (HBV DNA Positive[1×104 copies/mL or >2000 IU/ml], HCV RNA positive[>1×103 copies/mL]), or other hepatitis, cirrhosis])

17. Patients with autoimmune disease or suspected autoimmune disease (including but not limited to: myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, enteritis, multiple Sclerosis, vasculitis, glomerulonephritis, uveitis, hypophysitis, hyperthyroidism, etc.)

18. Patients who are allergic or suspected to be allergic to the study drug or similar drugs

19. Patients have other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (including mental diseases) that require concomitant treatment, and serious laboratory abnormalities. Accompanied by family or social factors, which will affect the safety of patients

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Dong sheng Zhang

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dongsheng Zhang, PhD

Role: PRINCIPAL_INVESTIGATOR

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China

Locations

Cancer center of SunYat-sen University

Guangzhou, Guangdong, China

Countries

China

References

Lu Y, Lin Q, Mo Y, Liu F, Zhang M, Huang R, Wang Y, Wang Y, Wang Z, Luo H, Guo G, Chen J, Liu Y, He M, Wang F, Wang F, Zhang D. Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study. Mol Cancer. 2025 Oct 2;24(1):235. doi: 10.1186/s12943-025-02437-0.

Reference Type: DERIVED

PMID: 41039600 (View on PubMed)

Other Identifiers

HMPL-012-SPRING-P104

Identifier Type: -

Identifier Source: org_study_id